Scientific Content

Dupilumab is Efficacious Regardless of Endoscopic Phenotype: Post Hoc Analysis of the LIBERTY EoE TREET Study

Dupilumab Maintained Histologic and Endoscopic Improvements During the Open-Label Extension Period of the EoE KIDS Study

LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

An easy guide to use Nirsevimab

ADCT – Atopic Dermatitis Control Tool

Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan

MS pulse - Tracking the hidden drivers of MS progression

MS pulse - Tracking the hidden drivers of MS progression

Advancing the Standard of Care: Addressing Progression in MS

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

Type II Summit 2025

Video Showcasing the Type II Summit 2025